Clodronate. A randomized study in the treatment of cancer-related hypercalcemia

R. S. Witte, J. Koeller, T. E. Davis, A. B. Benson, B. G. Durie, A. Lipton, J. L. Stock, D. L. Citrin, T. P. Jacobs

Research output: Contribution to journalArticle

26 Citations (Scopus)

Abstract

Malignancy-associated hypercalcemia is a common and recalcitrant problem. Current modes of therapy are often ineffective or prohibitively toxic. Clodronate disodium is a diphosphonate capable of inhibiting bone resorption resulting in a hypocalcemic effect. In this randomized, placebo-controlled study, we investigated the effect of hydration only (Rx-1) vs the effect of hydration plus either intravenously administered clodronate disodium, 4 mg/kg of body weight per day for three days (Rx-2) or intravenously administered clodronate disodium, 12 mg/kg of body weight given once only (Rx-3). By the third day of observation, Rx-2 produced a significant 2.8 mg/dL (0.70 mmol/L) reduction in serum calcium levels, whereas Rx-1 and Rx-3 did not produce a significant hypocalcemic effect when compared with baseline values. There were no toxicities observed. Intravenously administered clodronate appears to be an excellent agent for the acute treatment of malignancy-associated hypercalcemia.

Original languageEnglish (US)
Pages (from-to)937-939
Number of pages3
JournalArchives of Internal Medicine
Volume147
Issue number5
DOIs
StatePublished - Aug 3 1987

Fingerprint

Clodronic Acid
Second Primary Neoplasms
Hypercalcemia
Body Weight
Poisons
Diphosphonates
Bone Resorption
Neoplasms
Placebos
Observation
Calcium
Therapeutics
Serum

ASJC Scopus subject areas

  • Internal Medicine

Cite this

Witte, R. S., Koeller, J., Davis, T. E., Benson, A. B., Durie, B. G., Lipton, A., ... Jacobs, T. P. (1987). Clodronate. A randomized study in the treatment of cancer-related hypercalcemia. Archives of Internal Medicine, 147(5), 937-939. https://doi.org/10.1001/archinte.147.5.937
Witte, R. S. ; Koeller, J. ; Davis, T. E. ; Benson, A. B. ; Durie, B. G. ; Lipton, A. ; Stock, J. L. ; Citrin, D. L. ; Jacobs, T. P. / Clodronate. A randomized study in the treatment of cancer-related hypercalcemia. In: Archives of Internal Medicine. 1987 ; Vol. 147, No. 5. pp. 937-939.
@article{2a333cf8df72489d9bbf926707841f29,
title = "Clodronate. A randomized study in the treatment of cancer-related hypercalcemia",
abstract = "Malignancy-associated hypercalcemia is a common and recalcitrant problem. Current modes of therapy are often ineffective or prohibitively toxic. Clodronate disodium is a diphosphonate capable of inhibiting bone resorption resulting in a hypocalcemic effect. In this randomized, placebo-controlled study, we investigated the effect of hydration only (Rx-1) vs the effect of hydration plus either intravenously administered clodronate disodium, 4 mg/kg of body weight per day for three days (Rx-2) or intravenously administered clodronate disodium, 12 mg/kg of body weight given once only (Rx-3). By the third day of observation, Rx-2 produced a significant 2.8 mg/dL (0.70 mmol/L) reduction in serum calcium levels, whereas Rx-1 and Rx-3 did not produce a significant hypocalcemic effect when compared with baseline values. There were no toxicities observed. Intravenously administered clodronate appears to be an excellent agent for the acute treatment of malignancy-associated hypercalcemia.",
author = "Witte, {R. S.} and J. Koeller and Davis, {T. E.} and Benson, {A. B.} and Durie, {B. G.} and A. Lipton and Stock, {J. L.} and Citrin, {D. L.} and Jacobs, {T. P.}",
year = "1987",
month = "8",
day = "3",
doi = "10.1001/archinte.147.5.937",
language = "English (US)",
volume = "147",
pages = "937--939",
journal = "JAMA Internal Medicine",
issn = "2168-6106",
publisher = "American Medical Association",
number = "5",

}

Witte, RS, Koeller, J, Davis, TE, Benson, AB, Durie, BG, Lipton, A, Stock, JL, Citrin, DL & Jacobs, TP 1987, 'Clodronate. A randomized study in the treatment of cancer-related hypercalcemia', Archives of Internal Medicine, vol. 147, no. 5, pp. 937-939. https://doi.org/10.1001/archinte.147.5.937

Clodronate. A randomized study in the treatment of cancer-related hypercalcemia. / Witte, R. S.; Koeller, J.; Davis, T. E.; Benson, A. B.; Durie, B. G.; Lipton, A.; Stock, J. L.; Citrin, D. L.; Jacobs, T. P.

In: Archives of Internal Medicine, Vol. 147, No. 5, 03.08.1987, p. 937-939.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Clodronate. A randomized study in the treatment of cancer-related hypercalcemia

AU - Witte, R. S.

AU - Koeller, J.

AU - Davis, T. E.

AU - Benson, A. B.

AU - Durie, B. G.

AU - Lipton, A.

AU - Stock, J. L.

AU - Citrin, D. L.

AU - Jacobs, T. P.

PY - 1987/8/3

Y1 - 1987/8/3

N2 - Malignancy-associated hypercalcemia is a common and recalcitrant problem. Current modes of therapy are often ineffective or prohibitively toxic. Clodronate disodium is a diphosphonate capable of inhibiting bone resorption resulting in a hypocalcemic effect. In this randomized, placebo-controlled study, we investigated the effect of hydration only (Rx-1) vs the effect of hydration plus either intravenously administered clodronate disodium, 4 mg/kg of body weight per day for three days (Rx-2) or intravenously administered clodronate disodium, 12 mg/kg of body weight given once only (Rx-3). By the third day of observation, Rx-2 produced a significant 2.8 mg/dL (0.70 mmol/L) reduction in serum calcium levels, whereas Rx-1 and Rx-3 did not produce a significant hypocalcemic effect when compared with baseline values. There were no toxicities observed. Intravenously administered clodronate appears to be an excellent agent for the acute treatment of malignancy-associated hypercalcemia.

AB - Malignancy-associated hypercalcemia is a common and recalcitrant problem. Current modes of therapy are often ineffective or prohibitively toxic. Clodronate disodium is a diphosphonate capable of inhibiting bone resorption resulting in a hypocalcemic effect. In this randomized, placebo-controlled study, we investigated the effect of hydration only (Rx-1) vs the effect of hydration plus either intravenously administered clodronate disodium, 4 mg/kg of body weight per day for three days (Rx-2) or intravenously administered clodronate disodium, 12 mg/kg of body weight given once only (Rx-3). By the third day of observation, Rx-2 produced a significant 2.8 mg/dL (0.70 mmol/L) reduction in serum calcium levels, whereas Rx-1 and Rx-3 did not produce a significant hypocalcemic effect when compared with baseline values. There were no toxicities observed. Intravenously administered clodronate appears to be an excellent agent for the acute treatment of malignancy-associated hypercalcemia.

UR - http://www.scopus.com/inward/record.url?scp=0023276277&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0023276277&partnerID=8YFLogxK

U2 - 10.1001/archinte.147.5.937

DO - 10.1001/archinte.147.5.937

M3 - Article

C2 - 2953318

AN - SCOPUS:0023276277

VL - 147

SP - 937

EP - 939

JO - JAMA Internal Medicine

JF - JAMA Internal Medicine

SN - 2168-6106

IS - 5

ER -